Stockwatch

Date	Sym	Type	Headline
2024-04-18 16:30	UU:IKT	News Release200	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
2024-04-03 08:05	UU:IKT	News Release200	Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
2024-03-27 16:15	UU:IKT	News Release200	Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
2024-03-07 08:30	UU:IKT	News Release200	Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
2024-02-28 16:05	UU:IKT	News Release200	Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
2024-02-07 07:55	UU:IKT	News Release200	Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
2024-01-29 09:05	UU:IKT	News Release200	Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
2024-01-16 16:05	UU:IKT	News Release200	Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
2023-12-19 08:30	UU:IKT	News Release200	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
2023-12-04 08:35	UU:IKT	News Release200	Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
2023-11-14 16:30	UU:IKT	News Release200	Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
2023-11-07 09:29	UU:IKT	News Release200	Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
2023-11-07 08:00	UU:IKT	News Release200	Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
2023-10-16 07:00	UU:IKT	News Release200	Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson ¢ € ™s Disease and Provides Update on Ongoing Enrollment
2023-10-04 08:30	UU:IKT	News Release200	Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
2023-08-24 08:30	UU:IKT	News Release200	Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib
2023-08-22 08:05	UU:IKT	News Release200	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
2023-08-21 08:30	UU:IKT	News Release200	Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib
2023-08-17 08:30	UU:IKT	News Release200	Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
2023-08-14 16:20	UU:IKT	News Release200	Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
2023-08-07 08:05	UU:IKT	News Release200	Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
2023-07-17 16:05	UU:IKT	News Release200	Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
2023-06-29 09:29	UU:IKT	News Release200	Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
2023-06-22 08:05	UU:IKT	News Release200	Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
2023-06-21 08:05	UU:IKT	News Release200	Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease
2023-05-30 08:05	UU:IKT	News Release200	Inhibikase Therapeutics to Present at the LD Micro Invitational XIII
2023-05-24 12:05	UU:IKT	News Release200	Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
2023-05-16 07:45	UU:IKT	News Release200	Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
2023-05-15 08:30	UU:IKT	News Release200	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
2023-05-08 08:05	UU:IKT	News Release200	Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
2023-05-04 08:05	UU:IKT	News Release200	Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference